Picton Mahoney Asset Management’s NRX Pharmaceuticals NRXP Stock Holding History

Picton Mahoney Asset Management’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-13,327	Closed	-$897K	–	383
2020 Q2	$897K	Sell	13,327 -16,673	-56%	-$1.83M	0.05%	227
2020 Q1	$1.09M	Buy	30,000 +27,340	+1,028%	+$2.93M	0.06%	208
2019 Q4	$97K	Buy	+2,660	New	+$281K	0.01%	271

Other funds holding NRXP

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

BCM

Bluefin Capital Management New York $156M AUM 18.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Carson Wealth (CWM LLC) Omaha, Nebraska $38.1B AUM 19.66% 1-Year Est. Return

Picton Mahoney Asset Management's NRXP Position: Q3 2020 in Review

Picton Mahoney Asset Management sold out of NRX Pharmaceuticals (NRXP) in Q3 2020, closing a stake of 13,327 shares — an estimated $897K sold.

Picton Mahoney Asset Management first reported a position in NRXP in Q4 2019 and held it in 3 quarters. The position peaked at $1.09M in Q1 2020. 5 funds tracked by Wall St. Rank hold NRXP as of Q3 2020.

Picton Mahoney Asset Management reported no remaining NRX Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Picton Mahoney Asset Management sold 13,327 NRX Pharmaceuticals shares in Q3 2020, an estimated $897K.
Picton Mahoney Asset Management first reported a position in NRX Pharmaceuticals in Q4 2019 and held it in 3 quarters.
Picton Mahoney Asset Management's NRX Pharmaceuticals position peaked at $1.09M in Q1 2020.
5 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q3 2020.

Based on Picton Mahoney Asset Management's 13F filing for Q3 2020, filed 2 Nov 2020.